357P ADJUBIL: A phase II study of durvalumab and tremelimumab with or without capecitabine in ADJUvant BILiary tract cancer: The IKF/AIO-ADJUBIL trial. - Goetze, T.O.; Vogel, A.; Gonzalez Carmona, M.A.; Habibzade, T.; Reinecke, J.; Adler, M.; Pink, D.; Ettrich, T.J.; Roderburg, C.; Pession, U.; Saborowski, A.; Van Bömmel, F.; et al. (Annals of Oncology, 2025)